These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8608423)
1. New immunotherapies for sepsis. Young LS; Wenzel RP Proc Assoc Am Physicians; 1995 Oct; 107(3):361-4. PubMed ID: 8608423 [No Abstract] [Full Text] [Related]
3. Novel approaches to the treatment of sepsis: lessons learned and future directions. Cross A Shock; 1996; 6 Suppl 1():S71-4. PubMed ID: 8828101 [No Abstract] [Full Text] [Related]
4. Monoclonal antibodies for gram-negative sepsis. Med Lett Drugs Ther; 1991 Nov; 33(856):103-4. PubMed ID: 1943976 [No Abstract] [Full Text] [Related]
5. Sepsis trials. Intersection of investigation, regulation, funding, and practice. Bernard GR Am J Respir Crit Care Med; 1995 Jul; 152(1):4-10. PubMed ID: 7599855 [No Abstract] [Full Text] [Related]
6. [Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms]. Otero AJ; Linares M Rev Cubana Med Trop; 1998; 50(1):31-5. PubMed ID: 9842265 [TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria. Palliyil S; Broadbent ID Curr Opin Pharmacol; 2009 Oct; 9(5):566-70. PubMed ID: 19726227 [TBL] [Abstract][Full Text] [Related]
8. Update on monoclonal antibody therapy in the gram-negative sepsis syndrome. Hecker RB J Am Osteopath Assoc; 1992 Aug; 92(8):1017-20. PubMed ID: 1429060 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Baumgartner JD Infect Dis Clin North Am; 1991 Dec; 5(4):915-27. PubMed ID: 1723740 [TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy of severe gram-negative bacterial infections. Centoxin: a new drug under monitoring. National Committee for the Evaluation of Centoxin]. Pathol Biol (Paris); 1992 Dec; 40(10):975-6. PubMed ID: 1299810 [No Abstract] [Full Text] [Related]
11. Monoclonal antibodies to endotoxin in the management of sepsis. Fang KC West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126 [TBL] [Abstract][Full Text] [Related]
13. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis]. van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630 [No Abstract] [Full Text] [Related]
14. Human monoclonal antibodies in sepsis. de Koning J; Westendorp RG Neth J Med; 1991 Oct; 39(3-4):129-30. PubMed ID: 1791872 [No Abstract] [Full Text] [Related]
15. Molecular biology of endotoxin antagonism. Lazaron V; Dunn DL World J Surg; 2002 Jul; 26(7):790-8. PubMed ID: 11948366 [TBL] [Abstract][Full Text] [Related]
17. [Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome]. Boermeester MA; van Leeuwen PA; Schneider AJ; Houdijk AP; Ferwerda CC; Wesdorp RI Ned Tijdschr Geneeskd; 1993 Feb; 137(7):337-42. PubMed ID: 7679779 [No Abstract] [Full Text] [Related]
18. New therapeutic approaches in sepsis: a critical review. Eidelman LA; Pizov R; Sprung CL Intensive Care Med; 1995 Nov; 21 Suppl 2():S269-72. PubMed ID: 8636535 [No Abstract] [Full Text] [Related]
19. Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome. Tompkins RG Crit Care Med; 1994 Jan; 22(1):3. PubMed ID: 8124969 [No Abstract] [Full Text] [Related]
20. [Cytokines in the treatment of bronchial asthma]. Li M Zhonghua Jie He He Hu Xi Za Zhi; 1998 Aug; 21(8):507-9. PubMed ID: 11360527 [No Abstract] [Full Text] [Related] [Next] [New Search]